Here’s your chance to watch our free webinar, in association with CPD Solutions, on the canine Lymphoma Blood Test – Insights and Experience from First Opinion Practice. Presented by Iain Grant DipACVIM, The University of Glasgow, the webinar will provide you with a current overview of the increasing use of the canine Lymphoma Blood Test (cLBT) in first opinion practices and how it’s beginning to highlight new areas where the test can be helpful to both you and your clients.
This webinar will cover:
The current thinking around diagnosis and treatment of canine lymphoma.
Where the cLBT can help in this process, including the most difficult cases.
How the test has the potential to help with patient prognosis.
Where the cLBT can best be used when monitoring your chemotherapy patients.
THE CANINE LYMPHOMA BLOOD TEST – INSIGHTS AND EXPERIENCE FROM FIRST OPINION PRACTICE
A Webinar with Iain Grant DipACVIM,The University of Glasgow
Tuesday 1st December 2015, 7pm
Increasing use of the canine Lymphoma Blood Test (cLBT) in first opinion practices is beginning to highlight new areas where the test can be helpful to both practitioners and clients.
A number of cases have been observed with no obvious lymphadenopathy but with positive cLBT results and accompanying hypercalceamia. In each of these cases further investigation revealed an occult lymphoma located in either the spleen or GI tract.
Previously published data indicates that the cLBT is a good prognostic indicator for lymphoma. The cLBT score taken at diagnosis but prior to commencement of chemotherapy provides an indication of which cases should respond well to treatment and which might not. In the longitudinal study of 57 dogs all receiving the Wisconsin Madison protocol, median survival time (MST) for dogs having a cLBT score > 4.11 at diagnosis was 7 months, whereas dogs scoring between 3.29 and 4.10 had a MST of 16 months.
It is well known that the response rate drops for re-induction therapy following relapse. Determination of the cLBT score at relapse prior to commencing re-induction therapy can indicate the efficacy of re-induction. If the cLBT score does not reduce early in the re-induction phase, it could be prudent to consider a rescue protocol earlier than might otherwise be implemented.
Data and case studies will be presented which illustrate these applications of cLBT with specific reference to assisting first opinion practitioners in their treatment and monitoring of lymphoma in dogs. Examples of how the information derived from the cLBT can also benefit clients by keeping them well informed about the treatment and prognosis of lymphoma in their dog will also be presented.
To sign-up for the webinar, please follow the link:
Here’s your chance to watch our free webinar, in association with CPD Solutions, on canine lymphoma; current perspectives in diagnosis, treatment and monitoring. Presented by Arno Roos, DVM, the webinar will provide you with a current overview of the pathology of the lymphoma, options and advice on diagnosing the diseases, as well as current thinking on the range of chemotherapeutic regimens for the treatment of lymphoma.
If you are interested in learning more about the canine lymphoma blood test (cLBT), or have any questions on the webinar, please do not hesitate to contact firstname.lastname@example.org